Today: 9 June 2026
NuScale Power (SMR) stock jumps 13% today as nuclear shares rally — what’s driving the move
2 January 2026
1 min read

NuScale Power (SMR) stock jumps 13% today as nuclear shares rally — what’s driving the move

NEW YORK, Jan 2, 2026, 1:04 PM ET — Regular session

  • NuScale Power shares jumped about 13% in midday trading, outpacing the broader market.
  • Other nuclear-linked names also climbed, including Oklo and Nano Nuclear Energy.
  • Traders are watching next week’s U.S. labor-market data and the company’s next earnings timing.

Shares of NuScale Power Corp (NYSE:SMR) climbed on Friday, lifting the nuclear technology stock early in the first session of 2026. The shares were up 13.2% at $16.05, after touching $16.07, with about 17.6 million shares traded.

The move matters because NuScale sits in a pocket of the market where flows can dominate fundamentals for long stretches. Investors treat small modular reactor developers as a long-duration bet on future electricity demand, making the stocks sensitive to shifts in risk appetite.

Friday’s jump also stood out against a mixed tape, suggesting the bid was concentrated in theme trades rather than broad market momentum. Small caps edged up while large-cap and tech-heavy ETFs slipped.

Other nuclear and uranium-linked stocks moved higher in tandem. Oklo rose about 6.9%, Nano Nuclear Energy gained roughly 12.3%, and uranium miner Cameco added about 7.2%.

Nuclear operations also landed back in headlines overseas. Finnish operator Teollisuuden Voima said electricity production at its Olkiluoto 2 unit was interrupted after a fault during a software update triggered a “reactor trip” — an automatic shutdown designed to keep the plant safe. Cision News

Macro expectations remain a key swing factor for high-volatility growth stocks. “The next Fed Chair is probably going to be much more dovish than Jerome Powell,” said Dennis Dick, chief market strategist at Stock Trader Network, as investors looked ahead to next week’s U.S. labor-market data. Reuters

NuScale develops small modular reactors, or SMRs — smaller nuclear units designed to be built largely in factories and assembled into a full plant. The U.S. Nuclear Regulatory Commission approved NuScale’s 77-megawatt reactor design in 2025, clearing a major hurdle for its commercialization plans.

The company last updated investors on quarterly results on Nov. 6 and has not posted a new earnings release since then. Traders tend to focus on customer and financing updates alongside results because the company remains in the development-and-deployment phase.

NuScale’s investor events page currently lists no upcoming conferences. That leaves the next major scheduled catalyst as its next quarterly reporting cycle.

NuScale has not announced a date for fourth-quarter and full-year results, though market calendars currently project an early-March release. Investors will watch for updates on cash needs, funding plans and progress toward customer commitments.

With the stock trading in a wide intraday band, $16 has emerged as a near-term level traders are testing, while the prior close near $14 is the reference point for near-term support. Heavy volume points to active short-term positioning.

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
Interstellar comet 3I/ATLAS spills its secrets as scientists clock its water loss and radio silence
Previous Story

Interstellar comet 3I/ATLAS spills its secrets as scientists clock its water loss and radio silence

Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal
Next Story

Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal

Go toTop